Posts tagged product development
IntelGenx closes second tranche of convertible debenture financing

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a second tranche of its prospectus offering of convertible debentures, raising additional proceeds of CDN $762,000.

Read More
IntelGenx completes sale of convertible debentures

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a previously announced prospectus offering of convertible unsecured subordinated debentures for gross proceeds of more than $6.8-million.

Read More
IntelGenx files final prospectus for debenture offering

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has filed a final short form prospectus in connection with its previously announced offering of a minimum of $5-million and a maximum of $10-million principal amount of 8% convertible unsecured subordinated debentures due June 30, 2020.

Read More
IntelGenx, Tetra to develop Dronabinol XL tablet

IntelGenx (OTCQX:IGXT; TSXV:IGX) and Tetra Bio-Pharma (CSE:TBP; OTC:GRPOF) signed a definitive agreement to develop and commercialize a drug product containing the cannabinoid, Dronabinol, for the management of anorexia and cancer chemotherapy-related pain.

Read More
RepliCel pursuing non-diluting grant funding

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has retained The FreeMind Group, an international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private foundations.

Read More
Profound Medical COO joins XOR-Labs board

Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center for lung transplantation and a MaRS Innovation company.

Read More
Titan Pharma adds two members to BOD

Titan Pharmaceuticals (NASDAQ:TTNP), in a move to boost its product development and commercialization experience in the U.S., Europe and Asia, named Scott Smith and Dr. Rajinder Kumar to its board.

Read More
Avivagen closes private placement

Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million.

Each unit consists of one common share and one-half of a warrant at a price of six cents a unit. Each whole warrant entitles the holder to acquire one common share of Avivagen at a price of nine cents for two years from closing.

Read More